CervoMed Inc. 8-K

What Happened

• CervoMed Inc. (CRVO) filed an 8-K reporting the results of its Annual Meeting of Stockholders held June 8, 2026. Stockholders of record as of April 17, 2026 totaled 9,258,719 shares outstanding; 6,218,593 shares were represented at the meeting (≈67.2%), establishing a quorum.
• All eight director nominees were elected by plurality vote: John Alam, MD; Joshua S. Boger, PhD; Sylvie Grégoire, PharmD; Jane H. Hollingsworth, JD; Jeffrey V. Poulton; David Quigley; Marwan Sabbagh, MD; and Frank Zavrl. Each nominee received the requisite votes for election (individual "For" votes ranged ~3.13M–3.16M; each had ~29k–58k "Withheld" votes and 3,033,573 broker non-votes).
• Proposal results: RSM US LLP was ratified as independent registered public accounting firm (For 6,092,751; Against 21,433; Abstain 104,409). The advisory vote on executive compensation (say-on-pay) was approved (For 3,073,013; Against 104,221; Abstain 7,786; Broker non-votes 3,033,573). Amendment No. 1 to the CervoMed 2025 Equity Incentive Plan was approved (For 3,044,744; Against 132,860; Abstain 7,416; Broker non-votes 3,033,573).

Key Details

• Meeting date: June 8, 2026; Record Date: April 17, 2026. Shares outstanding: 9,258,719. Shares represented: 6,218,593 (~67.2%).
• All eight director nominees elected; each received ~3.13M–3.16M "For" votes and ~29k–58k "Withheld" votes; broker non-votes on director items: 3,033,573.
• Auditor ratified: RSM US LLP — 6,092,751 votes in favor.
• Say-on-pay and amendment to the 2025 Equity Incentive Plan were both approved by stockholders (see counts above); significant broker non-votes were recorded on non-routine matters.

Why It Matters

• Board continuity: Re-election of all eight directors means the current board and governance direction will continue without change for the coming year.
• Audit and governance: Ratification of RSM US LLP maintains continuity of the company’s independent auditor.
• Compensation and equity plan approvals: Shareholder approval of the advisory executive compensation vote and the equity plan amendment allows CervoMed to continue its executive pay framework and equity incentive program, which can affect future share-based awards and potential dilution.
• Voting dynamics: A large number of broker non-votes (3,033,573) on non-routine items indicates many shares held in street name did not participate in certain votes; investors should note turnout and voting patterns when assessing governance outcomes.